CELLPOINT

Cell Point (India) Share Price

 

 

Start SIP in CELLPOINT

Start SIP
Cell Point (India) live price: ₹13.55. It opened at ₹14 vs previous close ₹14; intraday high/low: ₹14/₹14. The 50 & 200 DMA stand at ₹15.65/₹18.39.

Cell Point (India) Performance

  • Low
  • ₹14
  • High
  • ₹14
  • 52 Week Low
  • ₹13
  • 52 Week High
  • ₹21
  • Open Price₹14
  • Previous Close₹14
  • Volume4,800
  • 50 DMA₹15.65
  • 100 DMA₹16.52
  • 200 DMA₹18.39

Investment Returns

  • Over 1 Month -13.69%
  • Over 3 Month -19.1%
  • Over 6 Month -27.35%
  • Over 1 Year -26.16%

Smart Investing Starts Here Start SIP with Cell Point (India) for Steady Growth!

Invest Now

Cell Point (India) Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 11.2
  • PEG Ratio
  • -
  • Market Cap Cr
  • 25
  • P/B Ratio
  • 0.3
  • Average True Range
  • 0.64
  • EPS
  • 0.2
  • Dividend Yield
  • 0
  • MACD Signal
  • -0.47
  • RSI
  • 33.53
  • MFI
  • 14.22

Cell Point (India) Financials

Cell Point (India) Technicals

EMA & SMA

Current Price
₹13.55
-0.3 (-2.17%)
pointer
  • Bearish Moving Average 16
  • Bullish Moving Average 0
  • 20 Day
  • ₹14.80
  • 50 Day
  • ₹15.65
  • 100 Day
  • ₹16.52
  • 200 Day
  • ₹18.39

Resistance and Support

13.65 Pivot Speed
  • R3 14.05
  • R2 13.95
  • R1 13.75
  • S1 13.45
  • S2 13.35
  • S3 13.15

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Cell Point (India) Ltd has an operating revenue of Rs. 822.88 Cr. on a trailing 12-month basis. An annual revenue growth of 1% is not great, Pre-tax margin of 1% needs improvement, ROE of 3% is fair but needs improvement. The company has a reasonable debt to equity of 1%, which signals a healthy balance sheet. From an O'Neil Methodology perspective, the stock has an EPS Rank of 19 which is a POOR score indicating inconsistency in earnings, a RS Rating of 38 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at E which indicates heavy supply, Group Rank of 115 indicates it belongs to a poor industry group of Telecom-Consumer Prods and a Master Score of D is close to being the worst. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment. Please note that this is a thinly traded stock.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Cell Point (India) Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-12-08 Others inter alia, To consider seeking Shareholders approval by way of postal ballot for appointment Mrs. Sailaja Penmetsa (DIN: 11354469), Non-executive Independent Director. Final Dividend of Re. 0.25/- (Twenty Five paisa) per equity share of Rs. 10/- each
2025-11-12 Quarterly Results
2025-09-02 Others To consider & approve 1. Draft Report from Board of directors for the financial year ended 31/03/2025. 2. Approve Date, Time, Venue, Notice of 12th AGM. 3. Other business matters. Final Dividend of Re. 0.25/- (Twenty Five paisa) per equity share of Rs. 10/- each
2025-05-29 Audited Results
2024-11-02 Quarterly Results

Cell Point (India) F&O

Cell Point (India) Shareholding Pattern

73.06%
24.29%
2.65%

About Cell Point (India)

  • NSE Symbol
  • CELLPOINT
  • BSE Symbol
  • Managing Director
  • Mr. Mohan Prasad Panday
  • ISIN
  • INE0O0001013

Similar Stocks to Cell Point (India)

Cell Point (India) FAQs

Cell Point (India) share price is ₹13 As on 18 March, 2026 | 00:00

The Market Cap of Cell Point (India) is ₹25.3 Cr As on 18 March, 2026 | 00:00

The P/E ratio of Cell Point (India) is 11.2 As on 18 March, 2026 | 00:00

The PB ratio of Cell Point (India) is 0.3 As on 18 March, 2026 | 00:00

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23